Neosoma HGG has received 510(k) clearance from the Food and Drug Administration (FDA). Neosoma HGG is an artificial intelligence-powered technology that may facilitate greater accuracy in the assessment of high-grade gliomas (HGGs) on brain magnetic resonance imaging (MRI).
Offering longitudinal tracking of patients with HGGs, Neosoma HGG provides tumor segmentation, facilitates imaging for 3D geometric analysis, and performs volumetric measurements, according to Neosoma, the manufacturer of Neosoma HGG.
In performance testing, Neosoma said the Neosoma HGG exceeded the assessment of individual neuroradiologists with a 95.5 percent accuracy rate in measuring the volume of HGGs at different points during a patient’s treatment course.
The company said the detailed objective measurements provided by Neosoma HGG aid in operative planning and the assessment of post-op progress, as well as the monitoring of chemotherapy treatment effectiveness.
“Clinicians usually debate the results of brain MRIs and whether the brain tumor is stable, responding to treatment, or progressing. Neosoma HHG will give us the objectivity needed to make our decisions easier and more accurate,” added Isabelle M. Germano, MD, MBA, FACS, a professor of neurosurgery and the director of the Comprehensive Brain Tumor Program, at Mount Sinai Medical Center.